Purpose: High tumor burden has emerged as a negative predictor of efficacy in chimeric antigen receptor T-cell therapy (CART) in patients with refractory or relapsed large B-cell lymphoma. This study analyzed the deviation among imaging-based tumor burden (TB) metrics and their association with progression-free (PFS) and overall survival (OS).

Materials And Methods: In this single-center observational study, we included all consecutively treated patients receiving CD19 CART with available baseline PET-CT imaging. Imaging-based TB was determined based on response evaluation criteria in lymphoma (RECIL), the Lugano criteria, and metabolic tumor volume. Total, nodal and extranodal TB were represented, according to the respective criteria, by sum of longest diameters (TB), sum of product of perpendicular diameters (TB), and metabolic tumor volume (TB). Correlation statistics were used for comparison. Proportional Cox regression analysis studied the association of TB metrics with PFS and OS.

Results: 34 consecutive patients were included (median age: 67 years, 41% female) with total median baseline TB of 12.5 cm, TB of 4,030 mm and TB of 330 mL. The correlation of TB and TB with TB was strong (ρ=0.744, p<0.001 and ρ=0.741, p<0.001), with lowest correlation for extranodal TB with TB (ρ=0.660, p<0.001). Stratification of PFS was strongest by total TB (HR=2.915, p=0.042), whereas total TB and total TB were not significant (both p>0.05). None of the total TB metrics were associated with OS (all p>0.05).

Conclusion: Pre-CART TB metrics vary significantly based on the assessment method, impacting their association with survival outcomes. The correlation between TB, TB and TB was influenced by disease phenotype and prior bridging therapy. TB method of assessment must be considered when interpreting the impact of TB on outcomes in clinical trials. Considering the heterogeneity, our results argue for standardization and harmonization across centers.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9492918PMC
http://dx.doi.org/10.3389/fonc.2022.974029DOI Listing

Publication Analysis

Top Keywords

tumor burden
12
metabolic tumor
12
chimeric antigen
8
antigen receptor
8
receptor t-cell
8
recil lugano
8
tumor volume
8
tumor
5
lymphoma tumor
4
burden chimeric
4

Similar Publications

Objectives: To develop a predictive tool to assist in predicting the risk of Acute Kidney Injury (AKI) following robot-assisted partial nephrectomy (RAPN).

Methods: A retrospective review was performed on the prospectively maintained, IRB-approved database to identify all consecutive patients who underwent RAPN between 2008 and 2023. Patients with end-stage kidney disease (ESKD), horseshoe kidneys, solitary kidneys, and previous renal transplant recipients were excluded.

View Article and Find Full Text PDF

Background: Anti-CD19 CAR T-cells have revolutionized outcomes in relapsed/refractory large B-cell lymphomas. Long-term follow-up underscored the role of hematological toxicity in non-relapse mortality, largely driven by infections, leading to the development of the CAR-HEMATOTOX (HT) score for predicting neutropenia. The European scientific community (EHA/EBMT) later reached a consensus, defining a new entity: immune effector cell-associated hematotoxicity (ICAHT).

View Article and Find Full Text PDF

Purpose: Outcomes for patients with advanced sarcomas are poor and there is a high unmet need to develop novel therapies. The purpose of this phase I study was to define the safety and efficacy of botensilimab (BOT), an Fc-enhanced anti-cytotoxic lymphocyte-association protein-4 antibody, plus balstilimab (BAL), an anti-PD-1 antibody, in advanced sarcomas.

Methods: BOT was administered intravenously (IV) at 1 mg/kg or 2 mg/kg once every 6 weeks in combination with BAL IV at 3 mg/kg once every 2 weeks for up to 2 years.

View Article and Find Full Text PDF

Background: Ras-GTPase-activating protein (GAP)-binding protein 1 (G3BP1) emerges as a pivotal oncogenic gene across various malignancies, notably including nasopharyngeal carcinoma (NPC). The use of automated image analysis tools for immunohistochemical (IHC) staining of particular proteins is highly beneficial, as it could reduce the burden on pathologists. Interestingly, there have been no prior studies that have examined G3BP1 IHC staining using digital pathology.

View Article and Find Full Text PDF

Background: The results of many large randomized clinical trials (RCTs) have transformed clinical practice in gastroesophageal reflux disease (GERD) and esophageal hiatal hernia (HH). However, research waste (i.e.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!